

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 29 October 2010 amounts to in total 214,249,813 shares, whereof 212,181,279 common shares and 2,068,534 class C shares, corresponding to in total 212,388,132.4 votes. The increase in the number of shares and votes results from an issue of 1,552,949 class C shares under Swedish Orphan Biovitrum's long term performance based share programs. The class C shares are intended to secure delivery of shares under the programs.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

For more information please contact:

Erik Kinnman, Vice President Investor Relations
Phone: +46 73 422 15 40
E-mail: erik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was provided for public release on 29 October 2010 at 10:00 a.m. CET.